AvKARE Lamotrigine Recall: Foreign Substance Contamination Exposes Supply Chain Vulnerabilities
AvKARE's Class III recall of Lamotrigine Tablets, USP, 150 mg, due to desiccant granule contamination, highlights critical quality control lapses. This event, coupled with AvKARE's prior recalls, signals heightened supply chain risks. Procurement and regulatory teams must intensify due diligence for products sourced from or distributed by AvKARE to mitigate potential disruptions.
FDA Findings: AvKARE's Lamotrigine Recall Due to Foreign Substance
On May 28, 2020, AvKARE Inc. initiated a Class III voluntary recall, designated D-1289-2020, for its Lamotrigine Tablets, USP, 150 mg. The critical reason for this action was the presence of a foreign substance, specifically granules consistent with desiccant packs, found within the product. This contamination poses a direct risk to patient safety, as ingestion of desiccant material is not intended and could lead to adverse health effects. The recall specifically impacted two lots: 25634 and 25633, both with an expiration date of September 30, 2021. The affected products were distributed nationwide across the U.S., encompassing 60-count bottles (NDC 42291-368-60) and 500-count bottles (NDC 42291-368-50). A total of 4,124 bottles were subject to this recall. For procurement directors and supply chain VPs, this event necessitates an immediate review of inventory and distribution channels for Lamotrigine sourced from AvKARE. The presence of foreign matter indicates a lapse in quality control during the packaging or storage phases, demanding a thorough re-evaluation of supplier qualification and incoming material inspection protocols. This incident underscores the importance of robust quality management systems to prevent contamination and ensure drug product integrity.
Facility Profile: AvKARE's Pulaski Formulation Operations Under Scrutiny
The recalled Lamotrigine Tablets were manufactured for AvKARE, Inc. at its facility in Pulaski, Tennessee (postal code 38478-2403). This site, identified as a formulation facility, plays a crucial role in AvKARE's product pipeline. The nature of the contamination—desiccant granules—suggests a breakdown in packaging process controls or storage conditions at this specific location. For regulatory affairs heads and business development executives, this incident highlights the necessity of stringent oversight for all manufacturing and packaging operations, even those seemingly routine. While the recall was initiated by the firm, the underlying cause points to potential deficiencies in Good Manufacturing Practices (GMP) related to facility design, equipment maintenance, or personnel training that allowed desiccant material to enter the finished product. Companies sourcing any pharmaceutical products, particularly generic drugs like Lamotrigine, from AvKARE's Pulaski facility must conduct enhanced due diligence. This includes reviewing their audit reports, quality agreements, and any corrective and preventive actions (CAPAs) implemented following this recall to ensure the integrity of their own supply chains and product portfolios.
Supply Chain Exposure: Mitigating Risks for Lamotrigine Procurement
The nationwide distribution of AvKARE's recalled Lamotrigine Tablets, USP, 150 mg, means that a broad spectrum of pharmaceutical distributors, pharmacies, and healthcare providers across the United States were potentially impacted. Lamotrigine, an essential anti-epileptic agent and mood stabilizer, is critical for managing conditions such as epilepsy and bipolar disorder. Any disruption in its supply can have significant clinical consequences. Procurement directors must immediately assess their current stock levels and future supply commitments for Lamotrigine from AvKARE. This recall serves as a critical reminder to diversify supplier bases for essential generic medications. Relying heavily on a single supplier, especially one with a documented history of quality issues, introduces unacceptable risk. Supply chain VPs should activate contingency plans, identify pre-qualified alternative suppliers for Lamotrigine, and evaluate the lead times required for transitioning orders. This proactive approach is vital to maintain uninterrupted patient access to critical medications and to safeguard business continuity against unforeseen quality events.
AvKARE's Regulatory History: A Pattern of Compliance Challenges
The Lamotrigine recall is not an isolated incident for AvKARE Inc., indicating a concerning pattern of regulatory compliance challenges. ChemLifeIntel's knowledge graph reveals two other significant recall events involving AvKARE. One notable event was a medium-severity recall of Dutasteride, which was attributed to impurity failures. This suggests issues extending beyond packaging, potentially impacting active pharmaceutical ingredient (API) quality or formulation integrity. More critically, AvKARE was also involved in a high-severity Class I recall due to a Trazodone-Sildenafil mix-up at a third-party facility. This incident highlights potential vulnerabilities in AvKARE's oversight of its contract manufacturing or packaging partners, or its internal quality release processes. For regulatory affairs heads and business development executives, this recurring pattern of recalls—ranging from foreign substance contamination to impurity issues and product mix-ups—signals a systemic risk in AvKARE's quality management and supply chain control. Companies engaging with AvKARE must recognize this elevated risk profile and implement rigorous supplier auditing and continuous monitoring programs to protect their own product integrity and market reputation.
Remediation and Future Outlook for AvKARE's Operations
The FDA officially terminated the Lamotrigine recall (D-1289-2020) on October 22, 2021, indicating that AvKARE Inc. had completed the necessary corrective actions to address the specific issue of desiccant contamination for the affected lots. While termination signifies the resolution of this particular recall event, it does not erase the broader implications of AvKARE's documented regulatory history. For senior decision-makers, this means that while the immediate threat from these specific Lamotrigine lots has passed, the underlying systemic issues that led to this and previous recalls may warrant continued scrutiny. Regulatory affairs teams should monitor AvKARE for any subsequent FDA inspections or enforcement actions, as a pattern of non-compliance can escalate to Warning Letters or Import Alerts, particularly if the issues are deemed systemic across multiple products or facilities. Procurement and supply chain VPs should maintain an elevated risk assessment for all AvKARE products, irrespective of individual recall status, and ensure robust alternative sourcing strategies are in place to mitigate future supply disruptions from this supplier.